Yuen, Man-FungMan-FungYuenChen, Chi-YiChi-YiChenCHUN-JEN LIUJeng, Wen-JueiWen-JueiJengElkhashab, MagdyMagdyElkhashabCoffin, Carla SCarla SCoffinKim, WonWonKimGreenbloom, SusanSusanGreenbloomRamji, AlnoorAlnoorRamjiLim, Young SYoung SLimKim, Yoon JYoon JKimFung, Scott KScott KFungKim, Dong JDong JKimJang, Jeong-WonJeong-WonJangLee, Kwan SikKwan SikLeeIyer, Radhakrishnan PRadhakrishnan PIyerMacfarlane, ChelseaChelseaMacfarlaneJackson, KathyKathyJacksonLocarnini, Stephen AStephen ALocarniniChan, Henry L YHenry L YChanAfdhal, Nezam HNezam HAfdhal2024-01-102024-01-102023-0114783223https://scholars.lib.ntu.edu.tw/handle/123456789/638372Novel agents acting against hepatitis B virus (HBV) are needed to improve HBsAg seroclearance or termed as 'functional cure'. Inarigivir (retinoic acid-inducible gene I agonist) has immunomodulatory and direct antiviral actions against HBV. We aimed to determine the safety and efficacy of Inarigivir for the treatment of HBV infection.enHBV DNA suppression; HBsAg level; Inarigivir; retinoic acid-inducible gene 1; tenofovirjournal article10.1111/liv.15465363006462-s2.0-85141999294https://api.elsevier.com/content/abstract/scopus_id/85141999294